No black box warning on record for Eraxis

As of the latest FDA labeling reviewed, Eraxis (ANIDULAFUNGIN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Eraxis medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hepatic Effects : Risk of abnormal liver tests, hepatitis, hepatic failure; monitor hepatic function during therapy. ( 5.1 , 13.2 ) • Hypersensitivity : Anaphylaxis, including shock has been reported. Risk of infusion-related adverse reactions, possibly histamine-mediated, including rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, and hypotension; to reduce

No black box warning on record for Eraxis

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hepatic Effects : Risk of abnormal liver tests, hepatitis, hepatic failure; monitor hepatic function during therapy. ( 5.1 , 13.2 ) • Hypersensitivity : Anaphylaxis, including shock has been reported. Risk of infusion-related adverse reactions, possibly histamine-mediated, including rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, and hypotension; to reduce

Eraxis Black Box Warning

No black box warning on record for Eraxis

Other warnings & precautions

Eraxis Black Box Warning

No black box warning on record for Eraxis

Other warnings & precautions